News | Radiation Therapy | April 26, 2017

Precision Medicine Poised to Change Brain Tumor Diagnostics and Treatment

Market is expected to grow substantially, thanks to the shift towards diagnosis and treatment using precision medicine-based options

Precision Medicine Poised to Change Brain Tumor Diagnostics and Treatment

April 26, 2017 — A new report on the brain cancer diagnostics market projects that up to 78,000 new cases of primary brain tumors are expected to be diagnosed globally in 2017, with approximately 25,000 found to be malignant.1 As research into precision medicine continues, both patients and healthcare professionals are anticipating greater use of this type of healthcare model in the diagnosis and treatment of brain tumors. Healthcare facilities that are already focused on precision medicine-based treatments, such as the San Diego Gamma Knife Center (SDGKC) are quickly setting the standard by which other treatment centers will be measured.

Precision medicine is a driving factor in the expansion of the brain cancer diagnostics and therapeutics market, which is expected to grow extensively through 2025 to reach a value of up to $773.1 million.2 Due to increasing interest, the federal government has allocated $34 billion to the National Institutes of Health this year for the sole purpose of advancing precision medicine research.3 This initiative is especially important for brain tumor patients: The current survival rate for patients with malignant forms of brain tumors is only about 34 percent, and for pediatric cancer patients, brain tumors account for up to 25 percent of all deaths.4,5

Traditionally, treatment methods for many types of brain tumors have included invasive biopsies and surgeries, along with interventions such as chemotherapy or radiation. These conventional therapies may continue for months or years — patients often have several brain surgeries, and must try multiple anticancer drugs before finding a medication that effectively treats their unique condition.4 Unfortunately for many, these treatments do not stop tumors from growing, and they often cause a host of severe side effects that profoundly affects their quality of life.5,6

As precision medicine-based research continues, scientists and physicians are finding that targeted approaches to treatment offer the most effective options when dealing with many types of brain tumors. Tools like the Gamma Knife stereotactic radiosurgery system can be used to precisely target tumors in the brain. In many cases where the Gamma Knife treatment option is utilized, brain tumors are successfully treated during one minimally invasive, outpatient appointment.

Paul Crowe, managing partner of the San Diego Gamma Knife Center (SDGKC), said, “Brain tumor patients have one of the hardest roads to travel when it comes to diagnosis and treatment. We’re confident that precision medicine is the right way to approach treatment, and since newer therapies can be tailored to each individual, successful treatment may be more likely.”

At the center of a precision medicine-based treatment approach is the patient. Using this type of healthcare model, clinicians and researchers work together with the patient to develop a highly-personalized plan of care based on the individual’s unique circumstances. This focus on precision medicine represents the beginning of a new era in medical care, especially as attempts are made to better understand and effectively treat many types of cancers.7

“By taking a precision medicine-based approach to treatment, we can help ensure that patients receive the most effective, most appropriate therapies to address their unique needs. Precision therapies such as the Gamma Knife offer a tailored treatment plan that can be modified depending on the patient’s particular situation and the location of the tumor. It’s exciting to be able to offer patients this highly targeted treatment option,” said Crowe.

Since its opening, the San Diego Gamma Knife Center has treated over 4,000 patients with various brain disorders from around the world. The facility is equipped to provide cutting-edge treatment for a variety of conditions, including metastatic brain tumors, primary brain tumors, arteriovenous malformations, and functional disorders such as trigeminal neuralgia and cluster headaches.

For more information: www.sdgkc.com

References

1. Brain Cancer Diagnostics Market: Global Industry Analysis and Opportunity Assessment 2016-2026. Future Marketing Insights. http://www.futuremarketinsights.com/reports/brain-cancer-diagnostics-market
2. Brain Tumor Diagnosis and Therapeutics Market Worth $773.1 Million by 2025. Grand View Research. http://www.grandviewresearch.com/press-release/global-brain-tumor-diagno...
3. Senate Committee Passes $34B NIH Budget for Precision Medicine. HealthIT Analytics. http://healthitanalytics.com/news/senate-passes-34b-nih-budget-to-advanc...
4. Quick Brain Tumor Facts. National Brain Tumor Society. http://braintumor.org/brain-tumor-information/brain-tumor-facts
5. Precision medicine can be used to treat pediatric brain cancer: Study. UPI. http://www.upi.com/Health_News/2017/01/19/Precision-medicine-can-be-used...
6. Precision Medicine and the Brain Tumor Community. Cure Forward. https://www.cureforward.com/blog/precision-medicine/precision-medicine-a...
7. Global Precision Medicine Market – Growth, Trends and Forecasts (2016 – 2021). Mordor Intelligence. https://www.mordorintelligence.com/industry-reports/precision-medicine-m...

 

Related Content

Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
MedLever Showcases Radiation Oncology Applications at ASTRO 2017
News | Radiation Therapy | October 05, 2017
MedLever demonstrated its flagship platform and applications that simplify clinical workflow, enable interoperability,...
Overlay Init